$403 Million is the total value of Ally Bridge Group (NY) LLC's 29 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 59.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDVL | MEDAVAIL HOLDINGS INC | $35,780,000 | -12.5% | 2,920,780 | 0.0% | 8.89% | +13.4% | |
| Sell | SPDR SER TRput | $27,080,000 | -75.0% | 200,000 | -75.0% | 6.73% | -67.7% | |
| NTRA | NATERA INC | $24,750,000 | +11.8% | 218,000 | 0.0% | 6.15% | +44.9% | |
| FATE | FATE THERAPEUTICS INC | $23,433,000 | +5.3% | 270,000 | 0.0% | 5.82% | +36.4% | |
| New | APELLIS PHARMACEUTICALS INCcall | $18,960,000 | – | 300,000 | +100.0% | 4.71% | – | |
| SYRS | Buy | SYROS PHARMACEUTICALS INC | $18,747,000 | -20.2% | 3,439,895 | +9.6% | 4.66% | +3.4% |
| ARVN | Buy | ARVINAS INC | $18,480,000 | +168.2% | 240,000 | +130.2% | 4.59% | +247.5% |
| CERE | Sell | CEREVEL THERAPEUTICS HLDNG I | $17,311,000 | -27.1% | 675,670 | -60.9% | 4.30% | -5.5% |
| RGEN | REPLIGEN CORP | $16,469,000 | +2.7% | 82,500 | 0.0% | 4.09% | +33.0% | |
| NUVB | Sell | NUVATION BIO INC | $15,902,000 | -23.9% | 1,708,091 | -14.6% | 3.95% | -1.4% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $15,728,000 | +38.3% | 859,910 | +26.3% | 3.91% | +79.1% |
| MRTX | New | MIRATI THERAPEUTICS INC | $15,345,000 | – | 95,000 | +100.0% | 3.81% | – |
| NAUT | New | NAUTILUS BIOTECHNOLOGY INC | $15,150,000 | – | 1,500,000 | +100.0% | 3.76% | – |
| NTLA | Sell | INTELLIA THERAPEUTICS INC | $15,078,000 | -16.5% | 93,127 | -58.6% | 3.75% | +8.2% |
| CYT | New | CYTEIR THERAPEUTICS INC | $13,414,000 | – | 626,843 | +100.0% | 3.33% | – |
| COGT | COGENT BIOSCIENCES INC | $13,159,000 | -7.6% | 1,622,591 | 0.0% | 3.27% | +19.7% | |
| NSTG | New | NANOSTRING TECHNOLOGIES INC | $11,986,000 | – | 185,000 | +100.0% | 2.98% | – |
| IDYA | Buy | IDEAYA BIOSCIENCES INC | $10,713,000 | +1419.6% | 510,407 | +1601.4% | 2.66% | +1871.1% |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $10,590,000 | -17.8% | 406,986 | 0.0% | 2.63% | +6.5% | |
| EPIX | ESSA PHARMA INC | $10,376,000 | -1.7% | 363,185 | 0.0% | 2.58% | +27.4% | |
| NVTA | New | INVITAE CORP | $10,119,000 | – | 300,000 | +100.0% | 2.51% | – |
| GOSS | New | GOSSAMER BIO INC | $9,541,000 | – | 1,175,000 | +100.0% | 2.37% | – |
| AVIR | Sell | ATEA PHARMACEUTICALS INC | $8,018,000 | -85.6% | 373,288 | -58.7% | 1.99% | -81.4% |
| BOLT | Buy | BOLT BIOTHERAPEUTICS INC | $6,374,000 | -32.7% | 412,267 | +43.3% | 1.58% | -12.7% |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $5,372,000 | -45.6% | 85,000 | -63.0% | 1.34% | -29.4% |
| ACET | ADICET BIO INC | $4,373,000 | -21.3% | 425,000 | 0.0% | 1.09% | +1.9% | |
| SBTX | SILVERBACK THERAPEUTICS INC | $3,972,000 | -29.2% | 128,572 | 0.0% | 0.99% | -8.3% | |
| FRLN | Sell | FREELINE THERAPEUTICS HLDGSsponsored ads | $3,274,000 | -34.9% | 401,747 | -1.7% | 0.81% | -15.7% |
| MGNX | New | MACROGENICS INC | $3,031,000 | – | 112,839 | +100.0% | 0.75% | – |
| LUNG | Exit | PULMONX CORP | $0 | – | -58,939 | -100.0% | -0.52% | – |
| ORTX | Exit | ORCHARD THERAPEUTICS PLCads | $0 | – | -547,427 | -100.0% | -0.76% | – |
| IMVT | Exit | IMMUNOVANT INC | $0 | – | -260,000 | -100.0% | -0.80% | – |
| FDMT | Exit | 4D MOLECULAR THERAPEUTICS IN | $0 | – | -150,000 | -100.0% | -1.25% | – |
| ITMR | Exit | ITAMAR MED LTDsponsored ads | $0 | – | -273,569 | -100.0% | -1.26% | – |
| CSTL | Exit | CASTLE BIOSCIENCES INC | $0 | – | -100,000 | -100.0% | -1.31% | – |
| OLK | Exit | OLINK HLDG ABsponsored ads | $0 | – | -200,000 | -100.0% | -1.38% | – |
| Exit | APTOSE BIOSCIENCES INC | $0 | – | -1,409,150 | -100.0% | -1.61% | – | |
| CVAC | Exit | CUREVAC N V | $0 | – | -110,000 | -100.0% | -1.93% | – |
| ORIC | Exit | ORIC PHARMACEUTICALS INC | $0 | – | -413,061 | -100.0% | -1.94% | – |
| ITOS | Exit | ITEOS THERAPEUTICS INC | $0 | – | -322,794 | -100.0% | -2.12% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 11 | Q2 2023 | 8.9% |
| UNUM THERAPEUTICS INC | 8 | Q3 2022 | 7.3% |
| RAPID MICRO BIOSYSTEMS INC-A | 8 | Q2 2023 | 3.5% |
| FATE THERAPEUTICS INC | 7 | Q2 2022 | 5.8% |
| VIRIDIAN THERAPEUTICS INC | 7 | Q2 2023 | 6.8% |
| SYROS PHARMACEUTICALS INC | 7 | Q2 2022 | 4.9% |
| REPLIGEN CORP | 7 | Q4 2022 | 6.5% |
| NAUTILUS BIOTECHNOLOGY INC | 7 | Q4 2022 | 3.8% |
| ARVINAS INC | 6 | Q1 2022 | 7.5% |
| NUVATION BIO INC | 6 | Q2 2022 | 4.9% |
View Ally Bridge Group (NY) LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | November 19, 2020 | 1,420,500 | 8.0% |
View Ally Bridge Group (NY) LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Ally Bridge Group (NY) LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.